
Some of the excitement has been taken out of Genmab’s full-year financial report, which will be publicized on Wednesday. The company’s partner Johnson & Johnson has already published figures for Genmab’s biggest source of revenue, cancer drug Darzalex.
Darzalex fourth quarter sales have been reported at USD 1.645bn compared to the estimated USD 1.636bn based on analysts’ predictions, which were collected by Bloomberg News.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app